WestEnd Advisors’s ResMed RMD Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$898 Hold
4
﹤0.01% 245
2025
Q4
$963 Hold
4
﹤0.01% 242
2025
Q3
$1.09K Sell
4
-2
-33% -$546 ﹤0.01% 220
2025
Q2
$1.55K Hold
6
﹤0.01% 172
2025
Q1
$1.34K Buy
6
+4
+200% +$934 ﹤0.01% 185
2024
Q4
$457 Hold
2
﹤0.01% 185
2024
Q3
$488 Hold
2
﹤0.01% 175
2024
Q2
$383 Hold
2
﹤0.01% 186
2024
Q1
$396 Hold
2
﹤0.01% 172
2023
Q4
$344 Hold
2
﹤0.01% 187
2023
Q3
$296 Buy
+2
New +$362 ﹤0.01% 198
2023
Q1
Sell
-2
Closed -$434 162
2022
Q4
$416 Hold
2
﹤0.01% 161
2022
Q3
$0 Hold
2
﹤0.01% 296
2022
Q2
$419 Buy
+2
New +$426 ﹤0.01% 147
2022
Q1
Sell
-1
Closed -$242 211
2021
Q4
$260 Buy
+1
New +$259 ﹤0.01% 228
2021
Q3
Hold
0
211
2021
Q2
Hold
0
222

Other funds holding RMD

WestEnd Advisors's RMD Position: Q1 2026 in Review

WestEnd Advisors held its ResMed (RMD) position steady in Q1 2026 at 4 shares worth $898. The position accounts for ﹤0.01% of the portfolio, ranked #245.

WestEnd Advisors first reported a position in RMD in Q4 2021 and has held it in 15 quarters since. The position peaked at $1.55K in Q2 2025. 938 funds tracked by Wall St. Rank hold RMD as of Q1 2026.

  • WestEnd Advisors held 4 shares of ResMed worth $898 as of Q1 2026.
  • WestEnd Advisors left its ResMed share count unchanged in Q1 2026.
  • ResMed made up ﹤0.01% of WestEnd Advisors's portfolio in Q1 2026, its #245 holding.
  • WestEnd Advisors first reported a position in ResMed in Q4 2021 and has held it in 15 quarters since.
  • WestEnd Advisors's ResMed position peaked at $1.55K in Q2 2025.
  • 938 funds tracked by Wall St. Rank held ResMed as of Q1 2026.

Based on WestEnd Advisors's 13F filing for Q1 2026, filed 22 Apr 2026.